{"filing":{"accession_number":"0001386570-26-000035","cik":"0001386570","ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"cdxc-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1386570/000138657026000035/cdxc-20260624.htm"},"events":[{"id":14686,"run_id":13081,"accession_number":"0001386570-26-000035","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 filing discloses the results of Niagen Bioscience's 2026 Annual Meeting of Stockholders, including voting outcomes for three proposals: election of eight directors, ratification of Crowe LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, and Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.","company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12188,"accession_number":"0001386570-26-000035","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Niagen Bioscience's 2026 Annual Meeting of Stockholders, including voting outcomes for three proposals: election of eight directors, ratification of Crowe LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, and Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:34:53.646590+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12188,"accession_number":"0001386570-26-000035","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Niagen Bioscience's 2026 Annual Meeting of Stockholders, including voting outcomes for three proposals: election of eight directors, ratification of Crowe LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, and Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:34:53.646590+00:00","company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","filing_date":"2026-06-29"}]}